A UK trial on whether the hypertension drug losartan can slow down Alzheimer’s disease will begin recruiting in August.
The multi-centre RADAR trial will be hosted by North Bristol Trust and funded with nearly £2m from the Medical Research Council. It will involve researchers from the University of Bristol, University of Cambridge and Queen’s University Belfast.
Losartan (Cazaar) is a angiotensin II receptor antagonist. Researchers believe the drug could slow down the progression of Alzheimer’s by improving brain blood flow and altering chemical pathways that cause brain cell damage, brain shrinkage and memory problems.
The Dementias and Neurodegenerative Diseases Research Network will work with participating sites to recruit 230 patients for the trial.
Funding for the study was announced by health secretary Jeremy Hunt on 20 December, as part of the prime minister’s Challenge on Dementia.